Drug companies looking to override negative district court losses in lawsuits aiming to delay further implementation of Medicare’s authority to negotiate lower drug prices faced continued skepticism in appellate court, where they sought to make their arguments that the negotiation program coerces companies to sell their drugs to Medicare at prices they don’t agree with and compels them to appear as though they agree with a negotiation process they oppose.